Printer Friendly

Apolipoprotein C-III, n-3 polyunsaturated fatty acids, and "insulin-resistant" T-455C APOC3 gene polymorphism in heart disease patients: example of gene-diet interaction.

The metabolism of circulating particles rich in triglycerides (TGs) [4] is strongly affected by their content in apolipoprotein C-111 (apo C-III), a component that inhibits the lipoprotein lipase-induced hydrolysis of these particles (1), and their apo E-mediated hepatic uptake (2). In recent years, clinical evidence supported the role of apo C-III and TG-rich lipoproteins in coronary artery disease (CAD) (3-9), suggesting that the apo C-III concentration is a reliable marker for lipoprotein concentration-associated CAD risk.

Different genetic and acquired factors influence serum apo C-III concentrations (10). Several polymorphic variants have been described in the APOC3 gene promoter, affecting protein transcription and synthesis (11); among them, promoter variants at positions -455 and -482 have been studied more extensively because of their altered affinity for the nuclear transcription factors that mediate the insulin response (12). APOC3 is transcriptionally down-regulated by insulin concentrations (13), but the presence of mutant sequences seems to reduce the inhibitory modulation of the hormone ("insulin resistance" at the gene level) (12).

Dietary factors, such as the consumption of long-chain n-3 polyunsaturated fatty acids (PUFAs) contained in fish and fish oil, have been also described to affect serum apo C-III concentrations through a mechanism similar to that exerted by fibrate lipid-lowering medications, which involves the activation of specific nuclear receptors, i.e., the so-called "peroxisome proliferator-activated receptor-[alpha]" (PPAR[alpha]) (14). APOC3 is one of the target genes transcriptionally down-regulated by PPAR[alpha] activation, thus contributing to the lipid- and lipoprotein-lowering properties of fish or fish oil intake (14). However, not all individuals within a population seem to gain the beneficial effects of a fish-rich diet. Genetic factors may render individuals differently susceptible as either "dietary responsive" or "dietary nonresponsive" (15).

Recently we reported that the T-455C variant on the APOC3 gene promoter is associated with increased TG and apo C-III concentrations (16,17) and represents an independent susceptibility factor for CAD (16), particularly in the presence of metabolic syndrome (17). However, in patients with high dietary intake, n-3 PUFAs could act as mediating factors able to substantially reduce the "over time impact" of APOC3 gene variants.

The fatty acid (FA) content in the erythrocyte membrane reflects previous intake over a relatively long time period (months), and an analysis by gas chromatography can provide information on multiple FAs, an approach superior to traditional dietary assessment methods (18). For this reason, erythrocyte FAs are considered as suitable biological markers for dietary intake, particularly for nutritional epidemiology purposes.

Taking into account all of these considerations, we analyzed apo C-III concentrations, erythrocyte FA concentrations, and APOC3 genotypes with the aim of evaluating possible interactions among these factors in determining circulating apo C-III concentrations in a large cohort of heart disease patients examined as part of the Verona Heart Project.

Patients and Methods


The details of the study have been reported previously (16). Briefly, we selected a total of 848 unrelated adult patients of both sexes who were recruited consecutively from those referred to the Institute of Cardiovascular Surgery or to the Cardiovascular-Hypertension Unit of the Department of Internal Medicine of the University of Verona in Italy and underwent coronary angiography (the Verona Heart Project). At the time of blood sampling, a complete clinical and pharmacologic history, including the presence or absence of the traditional CAD risk factors, was obtained. Of these patients, 590 had angiographically severe multivessel coronary atherosclerosis (CAD group), whereas 258 had normal coronary arteries (CAD-free) and underwent coronary angiography generally before surgical correction of valvular heart disease. Although CAD-free, these patients were therefore heart disease patients.

The study was approved by our Institutional Review Boards. Either written or oral informed consent was obtained from all patients.


Samples of venous blood were drawn from each patient in the free-living state, after an overnight fast. Serum lipids and the other common biochemical indices were measured as described previously (16). Apo A1, apo B, and apo E were measured by commercially available nephelometric immunoassays; antisera, calibrators, and the BNII nephelometer were from Dade Behring. Apo C-III was measured by a fully automated turbidimetric immunoassay. The reagent were obtained from Wako Pure Chemical Industries, and the procedure recommended by the manufacturer was implemented on a RxL Dimension Analyzer (Dade International Inc.). Imprecision was assessed on three pools of control sera with low, medium, and high concentrations of apo C-III. For the low, medium, and high concentrations, the intraassay CV was 1.8%, 2.0%, and 2.0%, respectively, and the interassay CV was 4.4%, 3.4%, and 2.3%.


The APOC3 T-455C polymorphism was analyzed as described previously (16).


All computations were performed with use of the STATA 8.0 statistical package (Stata Corp.). Distributions of continuous variables are reported as the mean (SD). Influences on apo C-III concentrations were first analyzed with log-transformed apo C-III concentrations as the variable of interest (outcome). Given the asymmetric and bimodal distribution of this variable (Fig. 1), gene--diet interaction effects were assessed by quantile regression models (19). Subsequently, interaction effects were analyzed by logistic models using as outcome the binary variable high apo C-III concentration (h-apo C-III), with the value 1 (and 0 otherwise) assigned to patients with an apo C-III concentration above than the 75th percentile of the apo C-III concentrations of the entire sample, after exclusion of the individuals taking lipid-lowering medications such as statins and/or fibrates (122 mg/L; see also Fig. 1, dashed line).

In both quantile and logistic models, the explanatory variables were the APOC3 genotype (in the recessive model, a binary variable takes the value 1 for homozygous -455CC individuals and 0 otherwise), the erythrocyte FA concentration (continuous variable), and the product of the two preceding variables (interaction term). The set of independent variables contained the following potential confounders: gender, age, CAD/CAD-free status, use of lipid-lowering medications (statins or other medications, including fibrates), smoking, and body mass index (BMI) (10, 20). In the logistic models, the statistical significance of the interaction term was tested by the likelihood ratio test.



The clinical features, the concentrations of the main erythrocyte FAs, and the T-455C allele and genotype frequencies of the patients, separated according to the diagnosis and considered as a whole, are summarized in Table 1.

As expected, several features associated with cardiovascular risk were differently distributed between individuals with CAD or without CAD, including the T-455C genotypes (16). Because the aim of the study was to detect possible gene-diet interaction effects in the whole population, these differences were not the object of specific analyses [with this in mind, compare Refs. (16) and (17)], but CAD/CAD-free status was taken into account as a confounder in the final logistic models (see below).

Apo C-III concentrations in the total patient population showed a bimodal and asymmetric distribution (median value, 105 mg/L; skewness value, 1.83) with a long tail for the highest values, as shown in Fig. 1. For this reason, the variance-stabilizing logarithmic transformation of apo C-III was used in all subsequent analyses.

Total erythrocyte PUFAs were significantly correlated with log-transformed apo C-III concentrations [correlation coefficient ([rho]) = -0.12; 95% confidence interval (CI), -0.18 to -0.05]. When the analysis was performed on the subgroups based on genotype, correlations remained significant for the patients with the -455TT ([rho] = -0.12; 95% CI, -0.23 to -0.01) and -455TC ([rho] = -0.15; 95% CI, -0.24 to -0.05) genotypes and in the combined TT + TC subgroup ([rho] = -0.14; 95% CI, -0.21 to -0.06) but not in the -455CC homozygous individuals ([rho] = -0.02; 95% CI, -0.19 to 0.15). Following this observation, we based further analyses on the assumption of a recessive model of interaction (patients carrying or not carrying the gene variant in homozygosity).

We first analyzed the possible gene-diet interactions able to influence apo C-III concentrations by quantile regression models using 50th, 65th, 75th, and 85th percentiles of the log-transformed apo C-III concentrations. By this approach, statistically significant interactions emerged when we modeled the 75th (or greater) percentile. The proportion of h-apo C-III individuals was therefore considered as a binary variable of interest (see the section on statistical analysis), and it was analyzed in relation to the different (low, intermediate, high) FA concentrations categorized according the tertile distributions in the population as a whole (below the 33th, 33th-66th, and above the 66th percentile, respectively, after exclusion of patients taking lipid-lowering medications). Of note, h-apo C-III individuals were characterized by an unfavorable lipid profile (increased TG, total cholesterol, and LDL-cholesterol concentrations) despite being similar in age, BMI, gender, and smoking status to the remaining population (data not shown). The proportions of h-apo C-III patients, plotted vs erythrocyte total PUFA concentrations, in the total population are shown in Fig. 2A; the corresponding distributions in the subgroups of individuals either carrying or not carrying the -455CC genotype are shown in Fig. 2, B and C. Both in the total population and in patients with the -455TT or -455CT genotype, an increasing erythrocyte PUFA concentration was associated with a progressively minor proportion of h-apo C-III patients (Fig. 2, A and B). This was not the case for -455CC homozygous individuals, in whom no substantial differences in the proportions of h-apo C-III patients were observed in connection with increasing total PUFA concentrations (Fig. 2C). In addition, we observed a surprisingly opposite association when the erythrocyte concentrations of n-3 PUFAs or docosahexaenoic acid (C22:o) were considered rather than total PUFAs; the proportion of h-apo C-III patients was highest in the subgroup of -455CC individuals with increased intake rather than in the subgroups with low or medium intake of n-3 PUFAs or C22:6 (Fig. 3).

We analyzed the effects of n-3 PUFA concentrations and APOC3 genotype and their interaction on the risk of having or not having increased apo C-III concentrations (h-apo C-III) by appropriate logistic models after adjustment for possible confounding variables (gender, age, CAD/CAD-free status, use of lipid-lowering medications, smoking status, and BMI). Shown in Tables 2 and 3 are the models for erythrocyte total PUFA, n-3 PUFA, and C22:6 concentrations and APOC3 genotypes estimated on the whole population and on the subsample of patients not taking lipid-lowering medications, respectively. We observed a significant interaction between -455CC homozygosity and erythrocyte C22:6 concentrations in both samples; in contrast, the interaction between genotype and n-3 PUFA concentration was statistically significant in patients not taking lipid-lowering medications but not in the total population. When similarly tested, we found no statistically significant results for other FAs in the n-3 family (e.g., C20:5 and C18:3).

To look for possible interactive effects on TG concentrations, we also applied the same statistical approach using either log-transformed TG concentrations or the proportion of patients with higher TG values (at or above the 75th percentile of the entire population after exclusion of patients taking lipid-lowering medications) as the dependent variable. However, we observed no statistically significant interactions between erythrocyte FA concentrations and APOC3 genotype.


Diet may influence the circulating lipoproteins in genetically predisposed individuals differently, but the determinants of this variability remain largely unknown (15). The results of the present study identify a different susceptibility to the apo C-111-lowering effects of a diet rich in n-3 PUFAs of fish origin in individuals carrying a polymorphic "insulin-resistant" variant on the APOC3 gene promoter. We observed a significant gene-diet interaction between homozygosity for the APOC3 -455C variant and erythrocyte n-3 PUFA or erythrocyte C22:6 concentrations. In the majority of the population (~85%), i.e., in individuals not carrying the -455CC genotype, increasing concentrations of these FAs in erythrocyte membranes were associated with a lower probability of having high concentrations of apo C-III; the finding was particularly clear in the subgroup of patients not receiving lipid-lowering treatment (Table 3). Such an association not only disappeared but had an opposite trend in -455CC homozygotes (Fig. 3C). Despite statistical significance and biological coherence of the interaction reported, our findings should be viewed with some caution, taking into account the limitation that our statistical interactions are based on a relatively small number of participants and that we looked at several aspects of apo C-111 distribution before concluding that there was a threshold effect.

To the best of our knowledge, this is the first report showing an APOC3 gene-diet interaction on apo C-III concentrations. Only a few studies have investigated the relationship between APOC3 gene polymorphisms and FA intake in determining the concentrations of plasma lipids, but the consequences on the protein product of that gene, i.e., the apo C-III values, have never been analyzed.

In 1996, Humphries et al. (21) reported that the APOC3 C-1100T polymorphism affects the consistency and magnitude of changes in plasma cholesterol in response to a diet high in polyunsaturated fats. In a study by Lopez-Miranda et al. (22), the SstI polymorphism, which arises from a cytosine-to-guanosine substitution in the 3'-untranslated region of the APOC3 gene, was shown to be associated with the changes in total and LDL-cholesterol induced by a diet rich in monounsaturated FAs. The same polymorphic variant was also reported to interact with smoking in determining plasma lipid responses to dietary changes (23). More recently, Brown et al. (24) demonstrated that a diet low in saturated fat, compared with a diet rich in saturated fat, was associated with a beneficial lipid profile (lower concentrations of apo B, total cholesterol, and LDL-cholesterol) only among individuals homozygous for of the APOC3 promoter 455T-625T polymorphism, whereas carriers of the APOC3 455C-625del allele were not responsive to a similar diet. Although different in study design, the report by Brown et al. (24), which is the only one reporting on the same APOC3 gene polymorphism as in our study, suggested that carriers of the APOC3 455C-625del allele receive no evident benefit from a diet poor in saturated FAs (and, as a necessary consequence, rich in unsaturated FAs). Unfortunately, data on apo C-III concentrations were not available in the report by Brown et al. (24) so that comparison with our findings can only be indirect.

Our results are consistent with the in vitro experimental evidence of an apo C-III-lowering effect generally exerted by n-3 FAs (14). This effect was attributable mainly to docosahexaenoic acid, the quantitatively most relevant FA of the n-3 family in our patients. The mechanism by which this FA acts on apo C-III production is not completely clear because the in vitro demonstration of activation of PPAR[alpha] receptors as a necessary step to lower apolipoprotein synthesis has recently been refuted by the results of a study on PPAR[alpha]-deficient animals (25). Our data concerning the insulin-resistant -455C APOC3 gene variant in humans support the hypothesis that n-3 FAs may interfere with the mechanism of APOC3 gene transcription and that it may be mediated to some extent by insulin or by nuclear factors operating on the APOC3 insulin-responsive element on the gene promoter. However, the matter is complex because individuals homozygous for -455C, -482T on the insulin-responsive element of the APOC3 gene should have lower insulin secretion after an oral glucose test (26). Although in our patients fasting insulin concentrations were not genotype related (17), a decreased incremental insulin response to physiologic stimuli could over time affect APOC3 gene transcription and apolipoprotein synthesis. Further studies are necessary to better clarify this point.

In combination with other positive biological effects, the hypolipidemic properties of n-3 PUFAs have been pharmacologically exploited to reduce CAD risk, and fish oil capsules are now recognized as useful medications in TG-associated dyslipidemia (27). For this reason, the conclusions derived from the present study may be of pharmacogenomic interest. The sample of heart disease patients recruited in the Verona Heart Project was not representative of the general population because many patients were males affected by CAD. The validity of our conclusions is therefore limited to this specific clinical setting, and it needs to be confirmed in a healthy population. In interpreting these results, however, it is important to emphasize that this is not a case-control study between CAD and CAD-free patients, but rather an analysis of interactions in a population in which CAD/ CAD-free status is one of the confounders. Adjustment for possible confounding variables (including CAD/CAD-free status) did not modify the results of the interaction models, supporting the view that the relationship between apo C-III concentrations, erythrocyte n-3 PUFA concentrations, and genotype is independent of the concurrent modifiers. Moreover, because the only firmly established therapeutic recommendation for n-3 PUFA supplementation is for patients with documented CAD (27), such as those enrolled in the present study, the value of the present results could be of clinical relevance.

Although this is not an intervention study, there is no logical reason to presume that dietary intake of n-3 PUFAs or fish oil capsules would yield qualitatively different effects. On the contrary, quantitative differences may play a role because the amounts of PUFAs ingested in fish oil capsules are generally much higher than those consumed in the diet. For example, the difference between the lowest and highest tertiles of the erythrocyte n-3 PUFA distribution in our population was 17-18%, whereas in intervention studies the corresponding difference between controls and treatment groups was 300400%, depending on the duration and dose of n-3 PUFA supplementation (28, 29). The inconsistency for an interactive diet-genotype effect on TG concentrations could be explained by this aspect, considering that a quantitatively more relevant change in n-3 PUFA intake is necessary to observe significant TG-lowering effects independently from any genetic influence (27).

In this respect, the beneficial n-3 PUFA effects could have been under- or overrated in the past, depending on the relative proportions of genetically nonresponsive individuals present in the different populations treated with fish oil capsules. Similarly, it is possible that in genetically selected patients, the advantages achieved by n-3 PUFA supplementation may in the future be shown to be even bigger than the effects demonstrated to date. Further genotype-tailored studies will be necessary to evaluate this possibility.

This work was supported by grants from the Ministry of University and Scientific and Technological Research, the Veneto Region Department of Health, and the Cariverona Foundation.


(1.) McConathy WJ, Gesquiere JC, Bass H, Tartar A, Fruchart JC, Wang CS. Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III. J Lipid Res 1992;33:995-1003.

(2.) Ginsberg HN, Le NA, Goldberg IJ, Gibson JC, Rubinstein A, Wang-Iverson P, et al. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest 1986;78:1287-95.

(3.) Blankenhorn DH, Alaupovic P, Wickham E, Chin HP, Azen SP. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts. Lipid and nonlipid factors. Circulation 1990;81:470-6.

(4.) Hodis HN, Mack WJ, Azen SP, Alaupovic P, Pogoda JM, LaBree L, et al. Triglyceride and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation 1994;90:42-9.

(5.) Mack WJ, Krauss RM, Hodis HN. Lipoprotein subclasses in the monitored atherosclerosis regression study (MARS). Treatment effects and relation to coronary angiographic progression. Arterioscler Thromb Vasc Biol 1996;16:697-704.

(6.) Luc G, Fievet C, Arveiler D, Evans AE, Bard JM, Cambien F. et al. Apolipoproteins C-III and E in apo B- and non-apo B-containing lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM study. J Lipid Res 1996;37:508-17.

(7.) Thompson GR. Angiographic evidence for the role of triglyceride-rich lipoproteins in progression of coronary artery disease. Eur Heart J 1998;19:H31-6.

(8.) Sacks FM, Alaupovic P, Moye LA, Cole TG, Sussex B, Stampfer MJ, et al. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the cholesterol and recurrent events (CARE) trial. Circulation 2000;102:1886-92.

(9.) Lee S-J, Campos H, Moye LA, Sacks FM. LDL particles containing apolipoprotein CIII are independent risk factors for coronary events in diabetic patients. Arterioscler Thromb Vasc Biol 2003; 23:853-8.

(10.) Tilly P, Sass C, Vincent-Viry M, Aguillon D, Siest G, Visvikis S. Biological and genetic determinants of serum apo C-III concentration: reference limits from the Stanislas cohort. J Lipid Res 2003;44:430-6.

(11.) Dammerman M, Sandkuijl LA, Halaas JL, Chung W, Breslow JL. An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3' untranslated region polymorphisms. Proc Natl Acad Sci U S A 1993;90:4562-6.

(12.) Li WW, Dammerman M, Smith JD, Metzger S, Breslow JL, Leff T. Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. J Clin invest 1995;96:2601-5.

(13.) Chen M, Breslow JL, Li W, Leff T. Transcriptional regulation of the apo C-III gene by insulin in diabetic mice: correlation with changes in plasma triglyceride levels. J Lipid Res 1994;35:1918-24.

(14.) Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res 1996;37: 907-25.

(15.) Ye SQ, Kwiterovich PO Jr. Influence of genetic polymorphisms on responsiveness to dietary fat and cholesterol. Am J Clin Nutr 2000;72(Suppl):1275S-84S.

(16.) Olivieri 0, Stranieri C, Bassi A, Zaia B, Girelli D, Pizzolo F, et al. Apolipoprotein CIII gene polymorphisms and risk of coronary artery disease. J Lipid Res 2002;43: 1450-7.

(17.) Olivieri O, Bassi A, Stranieri C, Trabetti E, Martinelli N, Pizzolo F, et al. Apolipoprotein CIII, metabolic syndrome and risk of coronary artery disease. J Lipid Res 2003;44:2374-81.

(18.) Arab L, Akbar J. Biomarkers and the measurement of fatty acids. Public Health Nutr 2002;5:865-71.

(19.) Koenker R, Bassett G. Regression quantiles. Econometrica 1978; 46:33-50.

(20.) Waterworth DM, Talmud P, Bujac SR, Fisher RM, Miller GJ, Humphries SE. Contribution of apolipoprotein C3 gene variants to determination of triglyceride levels and interaction with smoking in middle-aged men. Arterioscler Thromb Vasc Biol 2000;20: 2663-9.

(21.) Humphries SE, Talmud P, Cox C, Sutherland W, Mann J. Genetic factors affecting the consistency and magnitude of changes in plasma cholesterol in response to dietary challenge. QJM 1996; 89:671-80.

(22.) Lopez-Miranda J, Jansen S, Ordovas JM, Salas J, Marin C, Castro P, et al. Influence of the Sstl polymorphism at the apolipoprotein C-III gene locus on the plasma low-density-lipoprotein-cholesterol response to dietary monounsaturated fat. Am J Clin Nutr 1997; 66:97-103.

(23.) Perez-Martinez P, Gomez P, Paz E, Marin C, Gavilan Moral E, Lopez-Miranda J, et al. Interaction between smoking and the Sstl polymorphism of the apo C-III gene determines plasma lipid response to diet. Nutr Metab Cardiovasc Dis 2001;11:237-43.

(24.) Brown S, Ordovas JM, Campos H. Interaction between the APOC3 gene promoter polymorphisms, saturated fat intake and plasma lipoproteins. Atherosclerosis 2003;170:307-13.

(25.) Dallongeville J, Bauge E, Tailleux A, Peters JM, Gonzalez FJ, Fruchart JC, et al. Peroxisome proliferator-activated receptor [alpha] is not rate-limiting for the lipoprotein-lowering action of fish oil. J Biol Chem 2001;276:4634-9.

(26.) Waterworth DM, Talmud PJ, Luan J, Flavell DM, Byrne CD, Humphries SE, et al. Variants in the APOC3 insulin responsive element modulate insulin secretion and lipids in middle-aged men. Biochim Biophys Acta 2003;1637:200-6.

(27.) Kris-Etherton PM, Harris WS, Lawrence JA. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002;106:2747-57.

(28.) Vidgren HM, Agren JJ, Schwab U, Rissanen T, Hanninen O, Uusitupa MI. Incorporation of n-3 fatty acids into plasma lipid fractions, and erythrocyte membranes and platelets during dietary supplementation with fish, fish oil, and docosahexaenoic acid-rich oil among healthy young men. Lipids 1997;32:697-705.

(29.) Katan MB, Deslypere JP, van Birgelen AP, Penders M, Zegwaard M. Kinetics of the incorporation of dietary fatty acids into serum cholesteryl esters, erythrocyte membranes, and adipose tissue: an 18-month controlled study. J Lipid Res 1997;38:2012-22.


[1] Unit of Internal Medicine, Department of Clinical and Experimental Medicine, [2] Institute of Clinical Chemistry, and [3] Section of Biology and Genetics, Department of Mother and Child and Biology-Genetics, University of Verona, Verona, Italy.

[4] Nonstandard abbreviations: TG, triglyceride; apo, apolipoprotein; CAD, coronary artery disease; PUFA, polyunsaturated fatty acid; PPARa, peroxisome proliferator-activated receptor-[alpha]; FA, fatty acid; h-apo C-III, high apolipoprotein C-III; BMI, body mass index; and CI confidence interval.

* Address correspondence to this author at: Dipartmento Medicina Clinica e Sperimentale, Cattedra di Medicina Interna, University di Verona, Policlinico Borgo Roma, 37134 Verona, Italy. Fax 39-45-580111; e-mail oliviero.olivieri@

Received July 22, 2004; accepted November 1, 2004.

Previously published online at DOI: 10.1373/clinchem.2004.040477
Table 1. Clinical and biochemical features of the study
population (n = 848).

 CAD-free CAD
 Variables (a) (n = 258) (n = 590)

Mean (SD) age, years 58.3 (12.8) 60.5 (9.7)
Male gender, % 64.0 82.4
Patients receiving statin therapy, % 2.7 19.5
Patients receiving fibrate therapy, % 0.4 3.1
Mean (SD) BMI, kg/[m.sup.2] 25.2 (3.4) 26.7 (3.4)
Smokers, % 37.6 63.7
Hypertension, % 27.1 53.2
Diabetes, % 4.7 14.9
Mean (SD) creatinine, mmol/L 91.8 (18.4) 97.1 (25.5)
Mean (SD) total cholesterol, mmol/L 5.5 (1.1) 5.8 (1.1)
Mean (SD) LDL-cholesterol, mmol/L 3.5 (0.9) 3.9 (1.0)
Mean (SD) HDL-cholesterol, mmol/L 1.4 (0.4) 1.2 (0.3)
Mean (SD) triglycerides, mmol/L 1.5 (0.7) 2.0 (1.1)
Mean (SD) apo C-III, mg/L 108 (33) 121 (45)
Mean (SD) apo A1, g/L 1.4 (0.3) 1.3 (0.2)
Mean (SD) apo B, g/L 1.2 (0.3) 1.1 (0.3)
Mean (SD) apo E, g/L 0.045 (0.038) 0.046 (0.028)
Mean (SD) fibrinogen, g/L 3.2 (0.8) 3.6 (0.9)
Mean (SD) erythrocyte FAs, g/100 g
 C16:0 (palmitic acid) 22.8 (1.0) 22.8 (1.0)
 C18:0 (stearic acid) 17.0 (0.7) 17.2 (0.8)
 C18:1 (oleic acid) 14.0 (1.3) 14.1 (1.3)
 C18:2 (linoleic acid) 9.8 (1.4) 9.0 (1.4)
 C18:3 (linolenic acid) 0.102 (0.034) 0.093 (0.039)
 C20:4 (arachidonic acid) 19.0 (1.5) 19.1 (1.4)
 C20:5n-3 (eicosapentaenoic acid) 0.7 (0.3) 0.7 (0.3)
 C22:6n-3 (docosahexaenoic acid) 6.2 (1.2) 6.5 (1.4)
 Saturated FAs 48.8 (1.4) 49.0 (1.3)
 Monounsaturated FAs 14.8 (1.4) 14.9 (1.3)
 PUFAs 36.4 (1.5) 36.1 (1.4)
 Total unsaturated FAs 51.2 (1.4) 51.0 (1.3)
 n-3 PUFAs 7.3 (1.4) 7.7 (1.6)
 n-6 PUFAs 29.0 (1.8) 28.4 (1.7)
Apo C-III 455 allele frequency, %
 T 67.9 59.9
 C 32.1 41.1
APOC3 455 genotype frequency, %
 TT 45.0 35.9
 TC 45.8 46.0
 CC 9.2 18.1

 Variables (a) P (b)

Mean (SD) age, years 0.009
Male gender, % <0.001
Patients receiving statin therapy, % <0.001
Patients receiving fibrate therapy, % 0.009
Mean (SD) BMI, kg/[m.sup.2] <0.001
Smokers, % <0.001
Hypertension, % <0.001
Diabetes, % <0.001
Mean (SD) creatinine, mmol/L 0.002
Mean (SD) total cholesterol, mmol/L <0.001
Mean (SD) LDL-cholesterol, mmol/L <0.001
Mean (SD) HDL-cholesterol, mmol/L <0.001
Mean (SD) triglycerides, mmol/L <0.001
Mean (SD) apo C-III, mg/L <0.001
Mean (SD) apo A1, g/L <0.001
Mean (SD) apo B, g/L <0.001
Mean (SD) apo E, g/L NS (c)
Mean (SD) fibrinogen, g/L <0.001
Mean (SD) erythrocyte FAs, g/100 g
 C16:0 (palmitic acid) NS
 C18:0 (stearic acid) 0.009
 C18:1 (oleic acid) NS
 C18:2 (linoleic acid) <0.001
 C18:3 (linolenic acid) <0.001
 C20:4 (arachidonic acid) NS
 C20:5n-3 (eicosapentaenoic acid) NS
 C22:6n-3 (docosahexaenoic acid) <0.001
 Saturated FAs 0.004
 Monounsaturated FAs NS
 PUFAs 0.002
 Total unsaturated FAs 0.004
 n-3 PUFAs <0.001
 n-6 PUFAs <0.001
Apo C-III 455 allele frequency, % <0.001
APOC3 455 genotype frequency, % <0.001

(a) Continuous variables are reported as the mean (SD).

(b) Student t-test or [chi square] test when appropriate.

(c) NS, not significant.

Table 2. Estimation of the logistic models on the entire
population: Interaction effects between T--455C genotype
(recessive model) and erythrocyte total PUFA, n-3 PUFA, and C22:6
concentrations on the risk of having or not having increased apo
C-III concentrations.

 Logistic models (a)

 Variable b 95% CI

Erythrocyte total PUFAs (b) -0.33 -0.48 to -0.19
 Interaction term (c) 0.21 -0.14 to 0.55
Erythrocyte n-3 PUFAs (b) -0.10 -0.23 to 0.03
 Interaction term (c) 0.25 -0.02 to 0.52
Erythrocyte C22:6 (b) -0.14 -0.29 to 0.01
 Interaction term (c) 0.35 -0.04 to 0.66

 Variable Odds ratio P (b = 0 test)

Erythrocyte total PUFAs (b) 0.72 0.001
 Interaction term (c) 1.22 0.243
Erythrocyte n-3 PUFAs (b) 0.90 0.134
 Interaction term (c) 1.28 0.065
Erythrocyte C22:6 (b) 0.87 0.061
 Interaction term (c) 1.42 0.030

(a) Adjusted by gender, age, CAD-CAD-free status, use of
lipid-lowering medications, smoking, and BMI. b is the estimated
coefficient (slope).

(b) Continuous variable.

(c) Difference between the coefficient for the FAs in the 455CC
group minus the corresponding coefficient for the 455TT plus
455TC group.

Table 3. Estimation of the logistic models on the subsample of
patients not taking lipid-lowering medications: Interaction
effects between T--455C genotype (recessive model) and
erythrocyte total PUFAs, n-3 PUFAs, and C22:6 concentrations on
the risk of having or not having increased apo C-III

 Logistic models (a)

Variable b 95% CI

Erythrocyte total PUFAs (b) -0.25 -0.41 to -0.84
 Interaction term (c) 0.25 -0.15 to 0.65
Erythrocyte n-3 PUFAs (b) -0.17 -0.33 to -0.02
 Interaction term (c) 0.39 0.02 to 0.77
Erythrocyte C22:6 (b) -0.21 -0.38 to -0.04
 Interaction term (c) 0.44 0.02 to 0.85

Variable Odds ratio P (b = 0 test)

Erythrocyte total PUFAs (b) 0.78 0.003
 Interaction term (c) 1.29 0.214
Erythrocyte n-3 PUFAs (b) 0.84 0.028
 Interaction term (c) 1.48 0.039
Erythrocyte C22:6 (b) 0.81 0.089
 Interaction term (c) 1.54 0.040

(a) Adjusted by gender, age, CAD/CAD-free status, smoking, and
BMI. b is the estimated coefficient.

(b) Continuous variable.

(c) Difference between the coefficient for the FA in the 455CC
group minus the corresponding coefficient for the 455TT plus
455TC group.

Fig. 2 Erythrocyte PUFA concentrations and proportion of patients with
high apo-C III concentrations in the total population (A) and in the
APOC3 -455TT/-455TC (B) and -455CC (C) subgroups.

Patients with high apo C-III/total patients for each erythrocyte PUFA
tertile are indicated.


Patients with APO-C III >122 mg/L, %

<35.8 37/282 34.4
35.8-36.9 83/289 28.7
>36.9 62/277 22.4

PUFA (g/100g)


Patients with APO-C III >122 mg/L, %

<35.8 82/238 34.5
35.8-36.9 70/247 28.3
>36.9 47/231 20.3

PUFA (g/100g)


Patients with APO-C III >122 mg/L, %

<35.8 15/44 34.1
35.8-36.9 13/42 31
>36.9 15/46 32.6

PUFA (g/100g)

Note: Table made from bar graph.

Fig. 3. Erythrocyte n-3 PUFA and C22:6 concentrations and proportion
of patients with high apo-C III concentrations in the total population
(A) and in the APOC3 -455TT/-455TC (B) and -455CC (C) subgroups.

Patients with high apo C-III/total patients for each erythrocyte n-3
PUFA or C22:6 tertile are indicated.


Patients with APO-C III > 122 mg/L, %

n-3 PUFA (g/100g)

 n-3 PUFA

< 6.76 29.6 83/280

6.76-7.92 27.5 76/276

>7.92 28.4 83/292

 C 22:6

<5.72 30 83/277

5.72-6.75 28.2 78/277

> 6.75 27.6 81/294


n-3 PUFA (g/100g)

 n-3 PUFA

< 6.76 30.7 73/238

6.76-7.92 30.9 73/236

>7.92 26.7 63/236

<5.72 30.9 73.236

5.72-6.75 28 67/239

> 6.75 24.5 59/241

n-3 PUFA (g/100g)

 n-3 PUFA

< 6.76 23.8 10/42

6.76-7.92 24.4 10/41

>7.92 32.5 13/40

 C 22:6

<5.72 28.9 11/38

5.72-6.75 40 20/50

> 6.75 41.5 22/53

Note: Table made from bar graph.
COPYRIGHT 2005 American Association for Clinical Chemistry, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Lipids, Lipoproteins, and Cardiovascular Risk Factors
Author:Olivieri, Oliviero; Martinelli, Nicola; Sandri, Marco; Bassi, Antonella; Guarini, Patrizia; Trabetti
Publication:Clinical Chemistry
Date:Feb 1, 2005
Previous Article:The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations...
Next Article:Development of miniaturized competitive immunoassays on a protein chip as a screening tool for drugs.

Related Articles
An unusual case of severe hypertriglyceridemia and splenomegaly.
Candidate gene genotypes, along with conventional risk factor assessment, improve estimation of coronary heart disease risk in healthy UK men.
Apolipoprotein A5 and hypertriglyceridemia.
Lipid disorders and mutations in the APOB gene.
Additive effects of the PPAR[gamma], APOE, and FABP-2 genes in increasing Daylong triglycerides of normolipidemic women to concentrations comparable...
Effect of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic diseases.
Mutations in the apolipoprotein (apo) B-100 receptor-binding region: detection of apo B-100 ([Arg.sup.3500] [right arrow] Trp) associated with two...
The MTHFR C677T, APOE, and PON55 gene polymorphisms show relevant interactions with cardiovascular risk factors.
Low plasma vitamin A concentrations in familial combined hyperlipidemia.
Marine omega-3 fatty acids: protection from metabolic syndrome?

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters